Modification of soluble immunological parameters during treatment with interleukin-2.
In the present study we tested numerous soluble immunological parameters (soluble Interleukin 2 receptor, Beta 2 microglobulin, Neopterin, soluble CD8 antigen, gamma Interferon and alpha Tumor Necrosis Factor) in sera obtained from 18 advanced cancer patients during subcutaneous treatment with recombinant Interleukin 2. The treatment cycles consisted of a dose of 9 x 10(6) IU/m2 twice daily for 2 days followed by 1.8 x 10(6) IU/m2 twice daily for 5 days/week during 6 weeks. Even before therapy, neoplastic patients had higher levels of soluble Interleukin 2 receptor than a group of healthy subjects. Moreover, basal soluble CD8 antigen levels showed significant differences (p < 0.01) in patients with different clinical responses (responders and non-responders). During treatment we observed a fast increase (in the first or second week) of all parameters considered; soluble Interleukin 2 receptor and soluble CD8 antigen were the markers that were best related to the course of immunotherapy. In conclusion, monitoring recombinant Interleukin 2 immunotherapy with immunological parameters in serum seems to be of interest. However, more data are necessary to confirm the real value of the single markers.
Abbate
I
I
RIA Laboratory, Oncology Institute Bari, Italy.
Correale
M
M
Musci
M D
MD
Guida
M
M
Dragone
C D
CD
De Santis
M
M
De Lena
M
M
D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood / Q000276:immunology; D001708:Biopterins / Q000031:analogs & derivatives / Q000097:blood; D016827:CD8 Antigens / Q000097:blood; D016207:Cytokines / Q000096:biosynthesis; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000097:blood / Q000276:immunology / Q000628:therapy; D008297:Male; D008545:Melanoma / Q000097:blood / Q000276:immunology / Q000628:therapy; D008875:Middle Aged; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D019798:Neopterin; D015375:Receptors, Interleukin-2 / Q000378:metabolism; D011994:Recombinant Proteins / Q000627:therapeutic use; D012995:Solubility; D001613:beta 2-Microglobulin / Q000378:metabolism
D015415:Biomarkers; D014408:Biomarkers, Tumor; D016827:CD8 Antigens; D016207:Cytokines; D007376:Interleukin-2; D015375:Receptors, Interleukin-2; D011994:Recombinant Proteins; D001613:beta 2-Microglobulin; D001708:Biopterins; D019798:Neopterin